<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1099382</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Global status of research on cutaneous squamous cell carcinoma and its programmed cell death: Bibliometric and visual analysis from 2012 to middle 2022</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yalin</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Zhigang</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Huimin</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1164891"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Medical School, Huanghe Science &amp; Technology College</institution>, <addr-line>Zhengzhou, Henan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Yanan Jiang, Harbin Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Feng Jiang, Fudan University, China; Xue Liang Wu, First Affiliated Hospital of Hebei North University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Bo Li, <email xlink:href="mailto:libo_career@163.com">libo_career@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1099382</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Zhang, Guo, Wang and Li</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zhang, Guo, Wang and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>This study was aimed to analyze the research status and development trend of cutaneous squamous cell carcinoma (CSCC), focusing on the field of programmed cell death of CSCC, and providing suggestions for the research of CSCC.</p>
</sec>
<sec>
<title>Methods</title>
<p>The publications related to CSCC and CSCC programmed cell death were searched in the Web of Science Core Collection (WOSCC) database, and timespan was set from 2012 to middle 2022. Research trends, authors, major country collaborations, research institutions, representative journals, publishers, and keywords were analyzed with CiteSpace and VOSviewer.</p>
</sec>
<sec>
<title>Results</title>
<p>After screening, a total of 3656 publications on CSCC and 156 publications on CSCC cell programmed death were obtained. The number of published articles increased gradually with the years. The United States ranked first in terms of the number of published papers. Research in this field had focused on dermatology. Most of the institutions in both regions were from European and American countries. Harvard University was the most prolific institution. Wiley was the most prolific publisher. The popular keywords for programmed cell death in CSCC were cutaneous squamous cell carcinoma, diagnosis, pd 1, head, nivolumab and risk. Keywords in CSCC field were divided into 7 clusters: cutaneous squamous cell carcinoma, sentinel lymph node biopsy, skin cancer, B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) inhibitor and human Papillomaviruses, and P63 expression. Squamous cell carcinoma, cancer, head and expression were the most popular keywords. The popular keywords for programmed cell death in CSCC were cutaneous squamous cell carcinoma, diagnosis, pd 1, head, nivolumab and risk.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study analyzed the research status of cutaneous squamous cell carcinoma and programmed cell death from 2012 to middle 2022. Understanding research status and hotspots can help scholars, countries and policymakers to better understand the background and research frontier of CSCC, and guide further research directions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cutaneous squamous cell carcinoma</kwd>
<kwd>knowledge graph</kwd>
<kwd>bibliometric analysis</kwd>
<kwd>CiteSpace</kwd>
<kwd>VOSviewer</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="6"/>
<equation-count count="0"/>
<ref-count count="22"/>
<page-count count="12"/>
<word-count count="4846"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Cutaneous squamous cell carcinoma (CSCC) is a non-melanoma skin cancer, second only to basal cell carcinoma, accounting for 20% of skin cancers (<xref ref-type="bibr" rid="B1">1</xref>). The incidence of CSCCS is about 5 per 100,000, and the lifetime risk is 14-20%, which continues to increase each year (<xref ref-type="bibr" rid="B2">2</xref>). Statistics show that the incidence of CSCC has increased by at least 50% and even 200% in the past 30 years (<xref ref-type="bibr" rid="B3">3</xref>). These numbers are likely to continue to grow due to the ageing of the population and increasing awareness of these diseases.</p>
<p>Most CSCCS are formed by progressive progression of non-invasive precancerous lesions (<xref ref-type="bibr" rid="B4">4</xref>). CSCC results from genetic and epigenetic changes in cell replication during keratinosis. Over time, aggressive tumors accumulate and eventually form (<xref ref-type="bibr" rid="B5">5</xref>). When intracellular defensive abilities are impaired, the accumulation of genetic changes and the development of malignant and precancerous lesions are accelerated (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). For example, free radical damage caused by reactive oxygen species, deamination or de-purine is the cause of CSCC (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>In order to maintain normal physiological homeostasis, cells die in various ways so that the body can get rid of aged and damaged cells. The most well-studied programmed cell death types, like apoptosis, necrotizing apoptosis, high-temperature death, ferroptosis, pan-apoptosis, and autophagy, have been found to play a crucial role in regulating the immunosuppressive tumor microenvironment and even in determining the efficacy of cancer therapy. Surgery and a combination of chemotherapy and radiation have long been considered the gold standard option for advanced squamous cell carcinoma. The studies of the therapeutic methods to inhibit programmed cell death provide a new direction to improve the therapeutic effect.</p>
<p>So far, there is still no efficient prevention and treatment strategies for CSCC, and the research directions of programmed cell death of CSCC are gradually coming into scholar&#x2019;s vision. In order to comprehensively understand the research status and latest progress of CSCC, this paper adopts bibliometric method to analyze the publications related to CSCC and programmed cell death in WOSCC from 2012 to middle 2022. Combined with the two visualization tools, the main national cooperation, research institutions, representative articles, journals and publishers, research hotspots and frontiers in the field of CSCC and programmed cell death from 2012 to middle 2022 were reviewed, in order to provide suggestions for the research of CSCC.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Data collection</title>
<p>The literatures related to CSCC were searched in Core database based on WoSCC (<ext-link ext-link-type="uri" xlink:href="https://www.webofscience.com/wos/woscc/basic-search">https://www.webofscience.com/wos/woscc/basic-search</ext-link>). The data from WoSCC were comprehensive and standardized, and were widely used in bibliometrics. The retrieval strategies were &#x201c;Cutaneous squamous cell carcinoma (All Fields) &#x201c; and &#x201c;Cutaneous squamous cell carcinoma (All Fields) &#x201c;. The literature type was limited to article, the language was limited to English, the time span was set from 2012 to middle 2022, and the retrieval time was June 30, 2022.</p>
<p>The full records and references of all literatures and the name, publication year, country/region, institution, source publication, research direction, author, key words, address, citation of each literature were downloaded from the WoSCC in TXT file format. All the literatures were selected separately by the experts of the two teams and finally included.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Bibliometric analysis tools</title>
<p>At present, the development and application of big data risk control and intelligent medical treatment all involve knowledge graph (<xref ref-type="bibr" rid="B10">10</xref>). Knowledge mapping is an outstanding visualization method research in information, scientometrics, knowledge rules and graphic expression in recent years (<xref ref-type="bibr" rid="B11">11</xref>). Up to now, knowledge graph has become one of the frontiers of visualization research in various fields. Among them, VOSviewer (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>), a visualization software developed by Van Eck and Waltman of Leiden University in the Netherlands, and CiteSpace (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>), a visualization software developed by Chen Chaomei, a professor of computer and Information science at Drexel University in the United States, using the Java language, have attracted much attention. In this study, CiteSpace (Version 6.1.R2), VOSviewer (Version 1.6.10) and the literature statistics tools of WoSCC database were used to sort out and analyze CSCC related literatures, and verify the results of each other to ensure the accuracy of analysis. Set different analysis parameters according to different research contents.</p>
<p>CiteSpace is a common tool for mapping scientific knowledge. The aim is to visualize the structure, rules and distribution of scientific knowledge, and realize the mapping of author collaboration, keyword co-occurrence and institutional cooperation. Co-occurrence clusters, key nodes and research hotspots can be dynamically identified. At present, it has been widely used in the research hotspots and cooperative network analysis of medicine and health, humanities and philosophy, economic management, engineering and technology and other disciplines.</p>
<p>VOSviewer can also create visualizations. The difference is that the color of the circles represents different clusters, and the length of the line between the circles represents how close they are. Export the data of visual analysis, arrange the keywords according to the order of the average occurrence time, and get the current keywords; In the coauthored analysis, authors, institutions and countries are ranked according to link strength, and authors, institutions and countries with higher cooperative strength are obtained.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Main outcome indicators</title>
<p>The number of articles published by countries/regions, institutions, authors and journals, keyword co-occurrence and clustering, co-occurrence among authors, institutions and countries were the main analysis indicators.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Annual trend of paper publication</title>
<p>After literature screening by 2 researchers, a total of 3656 literatures were finally included in this study. These literatures were cited for a total of 62359 times from 2012 to middle 2022, and the average citation times of each item was 17.06 and h-index was 89, that is, at least 89 literatures were cited for 89 times. Among them, 156 articles were about programmed cell death, and the average citation times of each item was 12.54 and h-index was 25.</p>
<p>The number of published papers showed a wavy upward trend. In 2013, 268 articles were published, the lowest number in the last 11 years. Since then, the number of published papers has been increasing year by year, and it peaked at 480 in 2021, as shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>. In 2016, studies on programmed cell death of CSCC slowly came into view, and the number of studies involved in this field increased year by year and reached its peak in 2020, with 36 published in the whole year, and 100 articles related to programmed cell death of skin cancer were published from 2020 to middle 2022, accounting for 64.10% of the included literatures, as shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Number of literatures included in WoSCC from 2012 to 2022.<bold>(A)</bold>. Published literature on CSCC. <bold>(B)</bold>. Published literature on programmed cell death in skin cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g001.tif"/>
</fig>
<p>The number and trend of published literatures play an important role in understanding the research heat and development trend of a field. According to the retrieval results, the annual number and percentage of CSCC publications in the world from 2012 to middle 2022 are shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. In the past 11 years, the annual average number of articles published was more than 250, indicating that the research on CSCC has been the focus of scholars&#x2019; attention in the recent 11 years.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Annual publication volume and percentage.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Rank</th>
<th valign="bottom" align="center">Publication Years</th>
<th valign="bottom" align="center">Record Count</th>
<th valign="bottom" align="center">% of 3,656</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">1</td>
<td valign="bottom" align="center">2021</td>
<td valign="bottom" align="center">480</td>
<td valign="bottom" align="center">13.129</td>
</tr>
<tr>
<td valign="bottom" align="center">2</td>
<td valign="bottom" align="center">2020</td>
<td valign="bottom" align="center">453</td>
<td valign="bottom" align="center">12.391</td>
</tr>
<tr>
<td valign="bottom" align="center">3</td>
<td valign="bottom" align="center">2019</td>
<td valign="bottom" align="center">405</td>
<td valign="bottom" align="center">11.078</td>
</tr>
<tr>
<td valign="bottom" align="center">4</td>
<td valign="bottom" align="center">2016</td>
<td valign="bottom" align="center">351</td>
<td valign="bottom" align="center">9.601</td>
</tr>
<tr>
<td valign="bottom" align="center">5</td>
<td valign="bottom" align="center">2018</td>
<td valign="bottom" align="center">324</td>
<td valign="bottom" align="center">8.862</td>
</tr>
<tr>
<td valign="bottom" align="center">6</td>
<td valign="bottom" align="center">2015</td>
<td valign="bottom" align="center">315</td>
<td valign="bottom" align="center">8.616</td>
</tr>
<tr>
<td valign="bottom" align="center">7</td>
<td valign="bottom" align="center">2017</td>
<td valign="bottom" align="center">300</td>
<td valign="bottom" align="center">8.206</td>
</tr>
<tr>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">2014</td>
<td valign="bottom" align="center">280</td>
<td valign="bottom" align="center">7.659</td>
</tr>
<tr>
<td valign="bottom" align="center">9</td>
<td valign="bottom" align="center">2012</td>
<td valign="bottom" align="center">270</td>
<td valign="bottom" align="center">7.385</td>
</tr>
<tr>
<td valign="bottom" align="center">10</td>
<td valign="bottom" align="center">2013</td>
<td valign="bottom" align="center">268</td>
<td valign="bottom" align="center">7.33</td>
</tr>
<tr>
<td valign="bottom" align="center">11</td>
<td valign="bottom" align="center">2022</td>
<td valign="bottom" align="center">210</td>
<td valign="bottom" align="center">5.744</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Geographical distribution</title>
<p>In terms of the number of publications, the United States ranked first with an amount of 1,403, accounting for 38.375% of the total number of punlications, which has an absolute advantage. The top five countries were China, Germany, Australia and Italy. More than 70 percent of the articles were published by the top five countries, as shown in <xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A, B</bold>
</xref>. The country with the most publications on programmed cell death in skin cancer remains the United States, with 71 articles, followed by t Germany, Italy, Australia and Japan, as shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Published literature in countries/regions. <bold>(A)</bold>.The distribution trend of the top 10 countries/regions. <bold>(B)</bold>.Global map of countries/regions contributing to CSCC. <bold>(C)</bold>. National sequencing of CSCC cell programmed death studies. <bold>(D)</bold> Cooperation between countries in the CSCC field.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g002.tif"/>
</fig>
<p>Based on VOSViewer software, the geographic cooperation atlas of cutaneous squamous cell carcinoma research was established (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>), the nodes representing the United States are the largest, indicating that the United States is still the dominant country in this field. The next countries are China, the United Kingdom, Germany, Japan, etc., indicating that these countries have a certain research status in this field.</p>
<p>Using CiteSpace for statistical analysis, the first place is still the United States, with a centrality of 0.34, followed by the United Kingdom, Germany, France and Sweden, as shown in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>. In terms of centrality, the research results of the top ranked countries are more likely to be recognized by other countries.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Number and centrality of published literatures in different countries.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Rank</th>
<th valign="bottom" align="center">Countries/Regions</th>
<th valign="bottom" align="center">Record Count</th>
<th valign="bottom" align="center">% of 3,656</th>
<th valign="bottom" align="center">Rank</th>
<th valign="bottom" align="center">Countries/Regions</th>
<th valign="bottom" align="center">Centrality</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">1</td>
<td valign="bottom" align="center">USA</td>
<td valign="bottom" align="center">1403</td>
<td valign="bottom" align="center">38.375</td>
<td valign="bottom" align="center">1</td>
<td valign="middle" align="center">USA</td>
<td valign="middle" align="center">0.34</td>
</tr>
<tr>
<td valign="bottom" align="center">2</td>
<td valign="bottom" align="center">PEOPLES R CHINA</td>
<td valign="bottom" align="center">394</td>
<td valign="bottom" align="center">10.777</td>
<td valign="bottom" align="center">2</td>
<td valign="middle" align="center">ENGLAND</td>
<td valign="middle" align="center">0.18</td>
</tr>
<tr>
<td valign="bottom" align="center">3</td>
<td valign="bottom" align="center">GERMANY</td>
<td valign="bottom" align="center">328</td>
<td valign="bottom" align="center">8.972</td>
<td valign="bottom" align="center">3</td>
<td valign="middle" align="center">GERMANY</td>
<td valign="middle" align="center">0.15</td>
</tr>
<tr>
<td valign="bottom" align="center">4</td>
<td valign="bottom" align="center">AUSTRALIA</td>
<td valign="bottom" align="center">303</td>
<td valign="bottom" align="center">8.288</td>
<td valign="bottom" align="center">4</td>
<td valign="middle" align="center">FRANCE</td>
<td valign="middle" align="center">0.1</td>
</tr>
<tr>
<td valign="bottom" align="center">5</td>
<td valign="bottom" align="center">ITALY</td>
<td valign="bottom" align="center">290</td>
<td valign="bottom" align="center">7.932</td>
<td valign="bottom" align="center">5</td>
<td valign="middle" align="center">SWITZERLAND</td>
<td valign="middle" align="center">0.09</td>
</tr>
<tr>
<td valign="bottom" align="center">6</td>
<td valign="bottom" align="center">ENGLAND</td>
<td valign="bottom" align="center">269</td>
<td valign="bottom" align="center">7.358</td>
<td valign="bottom" align="center">6</td>
<td valign="middle" align="center">NETHERLANDS</td>
<td valign="middle" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">7</td>
<td valign="bottom" align="center">FRANCE</td>
<td valign="bottom" align="center">191</td>
<td valign="bottom" align="center">5.224</td>
<td valign="bottom" align="center">7</td>
<td valign="middle" align="center">SCOTLAND</td>
<td valign="middle" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">JAPAN</td>
<td valign="bottom" align="center">166</td>
<td valign="bottom" align="center">4.54</td>
<td valign="bottom" align="center">8</td>
<td valign="middle" align="center">PEOPLES R CHINA</td>
<td valign="middle" align="center">0.06</td>
</tr>
<tr>
<td valign="bottom" align="center">9</td>
<td valign="bottom" align="center">SPAIN</td>
<td valign="bottom" align="center">151</td>
<td valign="bottom" align="center">4.13</td>
<td valign="bottom" align="center">9</td>
<td valign="middle" align="center">ITALY</td>
<td valign="middle" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">10</td>
<td valign="bottom" align="center">NETHERLANDS</td>
<td valign="bottom" align="center">113</td>
<td valign="bottom" align="center">3.091</td>
<td valign="bottom" align="center">10</td>
<td valign="middle" align="center">SPAIN</td>
<td valign="middle" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">11</td>
<td valign="bottom" align="center">SWITZERLAND</td>
<td valign="bottom" align="center">107</td>
<td valign="bottom" align="center">2.927</td>
<td valign="bottom" align="center">11</td>
<td valign="middle" align="center">JAPAN</td>
<td valign="middle" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">12</td>
<td valign="bottom" align="center">INDIA</td>
<td valign="bottom" align="center">100</td>
<td valign="bottom" align="center">2.735</td>
<td valign="bottom" align="center">12</td>
<td valign="middle" align="center">NORWAY</td>
<td valign="middle" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">13</td>
<td valign="bottom" align="center">BRAZIL</td>
<td valign="bottom" align="center">89</td>
<td valign="bottom" align="center">2.434</td>
<td valign="bottom" align="center">13</td>
<td valign="middle" align="center">CZECH REPUBLIC</td>
<td valign="middle" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">14</td>
<td valign="bottom" align="center">CANADA</td>
<td valign="bottom" align="center">86</td>
<td valign="bottom" align="center">2.352</td>
<td valign="bottom" align="center">14</td>
<td valign="middle" align="center">AUSTRALIA</td>
<td valign="middle" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">15</td>
<td valign="bottom" align="center">SOUTH KOREA</td>
<td valign="bottom" align="center">82</td>
<td valign="bottom" align="center">2.243</td>
<td valign="bottom" align="center">15</td>
<td valign="middle" align="center">CANADA</td>
<td valign="middle" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">16</td>
<td valign="bottom" align="center">SCOTLAND</td>
<td valign="bottom" align="center">76</td>
<td valign="bottom" align="center">2.079</td>
<td valign="bottom" align="center">16</td>
<td valign="middle" align="center">SWEDEN</td>
<td valign="middle" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">17</td>
<td valign="bottom" align="center">TURKEY</td>
<td valign="bottom" align="center">69</td>
<td valign="bottom" align="center">1.887</td>
<td valign="bottom" align="center">17</td>
<td valign="middle" align="center">SAUDI ARABIA</td>
<td valign="middle" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">18</td>
<td valign="bottom" align="center">AUSTRIA</td>
<td valign="bottom" align="center">55</td>
<td valign="bottom" align="center">1.504</td>
<td valign="bottom" align="center">18</td>
<td valign="middle" align="center">AUSTRIA</td>
<td valign="middle" align="center">0.02</td>
</tr>
<tr>
<td valign="bottom" align="center">19</td>
<td valign="bottom" align="center">FINLAND</td>
<td valign="bottom" align="center">53</td>
<td valign="bottom" align="center">1.45</td>
<td valign="bottom" align="center">19</td>
<td valign="middle" align="center">DENMARK</td>
<td valign="middle" align="center">0.02</td>
</tr>
<tr>
<td valign="bottom" align="center">20</td>
<td valign="bottom" align="center">SWEDEN</td>
<td valign="bottom" align="center">53</td>
<td valign="bottom" align="center">1.45</td>
<td valign="bottom" align="center">20</td>
<td valign="middle" align="center">POLAND</td>
<td valign="middle" align="center">0.02</td>
</tr>
<tr>
<td valign="bottom" align="center">21</td>
<td valign="bottom" align="center">DENMARK</td>
<td valign="bottom" align="center">50</td>
<td valign="bottom" align="center">1.368</td>
<td valign="bottom" align="center">21</td>
<td valign="middle" align="center">MEXICO</td>
<td valign="middle" align="center">0.02</td>
</tr>
<tr>
<td valign="bottom" align="center">22</td>
<td valign="bottom" align="center">NEW ZEALAND</td>
<td valign="bottom" align="center">49</td>
<td valign="bottom" align="center">1.34</td>
<td valign="bottom" align="center">22</td>
<td valign="middle" align="center">BRAZIL</td>
<td valign="middle" align="center">0.01</td>
</tr>
<tr>
<td valign="bottom" align="center">23</td>
<td valign="bottom" align="center">GREECE</td>
<td valign="bottom" align="center">48</td>
<td valign="bottom" align="center">1.313</td>
<td valign="bottom" align="center">23</td>
<td valign="middle" align="center">GREECE</td>
<td valign="middle" align="center">0.01</td>
</tr>
<tr>
<td valign="bottom" align="center">24</td>
<td valign="bottom" align="center">BELGIUM</td>
<td valign="bottom" align="center">42</td>
<td valign="bottom" align="center">1.149</td>
<td valign="bottom" align="center">24</td>
<td valign="middle" align="center">BELGIUM</td>
<td valign="middle" align="center">0.01</td>
</tr>
<tr>
<td valign="bottom" align="center">25</td>
<td valign="bottom" align="center">POLAND</td>
<td valign="bottom" align="center">40</td>
<td valign="bottom" align="center">1.094</td>
<td valign="bottom" align="center">25</td>
<td valign="middle" align="center">PORTUGAL</td>
<td valign="middle" align="center">0.01</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Subject attribution analysis</title>
<p>Studies in this field mainly focus on Dermatology (1194, 32.623%). The other main research directions were Oncology (811 articles, 22.158%), Surgery (428 articles, 11.694%), Pathology (310 articles, 8.470%), General Internal Medicine (201 articles, 5.492%). More than 80% of the literature on squamous cell carcinoma of the skin focuses were in the top 5 research directions, as shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Analysis of research direction.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g003.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Analysis of main institutions</title>
<p>Most of the top 25 institutions in the field of CSCC are from western countries. Among them, Harvard University published 294 papers, which is the institution with the most publications. The University of California System published 165 papers, and the University of Texas System published 143 papers, ranking second and third respectively. University of London, Ut Md Anderson Cancer Center and University of Sydney published more than 100 papers in this field, with 111, 101 and 100 papers respectively (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>; <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Literature analysis published by institutions. <bold>(A)</bold>. A statistical chart of the number of articles published by the top 10 institutions on CSCC research. <bold>(B)</bold>.Timeline and cluster view of all commonly referenced institutions. <bold>(C)</bold>.Excellent institutional coauthored analysis of the CSCC field. <bold>(D)</bold>.Excellent institutional co-citation analysis in the CSCC field. <bold>(E)</bold>.A statistical chart of the number of articles published by the top 20 institutions on CSCC cell programmed death studies. <bold>(F)</bold>.Excellent institutional coauthored analysis of the CSCC cell programmed death field.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g004.tif"/>
</fig>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Number and centrality of published literatures in different institution.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Institution</th>
<th valign="middle" align="center">Record Count</th>
<th valign="middle" align="center">% of 3,656</th>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Institution</th>
<th valign="middle" align="center">Centrality</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">1</td>
<td valign="bottom" align="center">Harvard University</td>
<td valign="bottom" align="center">294</td>
<td valign="bottom" align="center">8.042</td>
<td valign="bottom" align="center">1</td>
<td valign="bottom" align="center">Queen Mary University London</td>
<td valign="bottom" align="center">0.11</td>
</tr>
<tr>
<td valign="bottom" align="center">2</td>
<td valign="bottom" align="center">University of California System</td>
<td valign="bottom" align="center">165</td>
<td valign="bottom" align="center">4.508</td>
<td valign="bottom" align="center">2</td>
<td valign="bottom" align="center">University Modena &amp; Reggio Emilia</td>
<td valign="bottom" align="center">0.09</td>
</tr>
<tr>
<td valign="bottom" align="center">3</td>
<td valign="bottom" align="center">University of Texas System</td>
<td valign="bottom" align="center">143</td>
<td valign="bottom" align="center">3.907</td>
<td valign="bottom" align="center">3</td>
<td valign="bottom" align="center">University Toronto</td>
<td valign="bottom" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">4</td>
<td valign="bottom" align="center">University of London</td>
<td valign="bottom" align="center">111</td>
<td valign="bottom" align="center">3.033</td>
<td valign="bottom" align="center">4</td>
<td valign="bottom" align="center">University Dundee</td>
<td valign="bottom" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">5</td>
<td valign="bottom" align="center">Ut Md Anderson Cancer Center</td>
<td valign="bottom" align="center">101</td>
<td valign="bottom" align="center">2.76</td>
<td valign="bottom" align="center">5</td>
<td valign="bottom" align="center">Mem Sloan Kettering Cancer Ctr</td>
<td valign="bottom" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">6</td>
<td valign="bottom" align="center">University of Sydney</td>
<td valign="bottom" align="center">100</td>
<td valign="bottom" align="center">2.732</td>
<td valign="bottom" align="center">6</td>
<td valign="bottom" align="center">German Cancer Res Ctr</td>
<td valign="bottom" align="center">0.08</td>
</tr>
<tr>
<td valign="bottom" align="center">7</td>
<td valign="bottom" align="center">Massachusetts General Hospital</td>
<td valign="bottom" align="center">91</td>
<td valign="bottom" align="center">2.486</td>
<td valign="bottom" align="center">7</td>
<td valign="bottom" align="center">University Sydney</td>
<td valign="bottom" align="center">0.07</td>
</tr>
<tr>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">German Cancer Research Center Dkfz</td>
<td valign="bottom" align="center">83</td>
<td valign="bottom" align="center">2.268</td>
<td valign="bottom" align="center">8</td>
<td valign="bottom" align="center">Massachusetts Gen Hosp</td>
<td valign="bottom" align="center">0.07</td>
</tr>
<tr>
<td valign="bottom" align="center">9</td>
<td valign="bottom" align="center">Helmholtz Association</td>
<td valign="bottom" align="center">83</td>
<td valign="bottom" align="center">2.268</td>
<td valign="bottom" align="center">9</td>
<td valign="bottom" align="center">University Calif San Francisco</td>
<td valign="bottom" align="center">0.06</td>
</tr>
<tr>
<td valign="bottom" align="center">10</td>
<td valign="bottom" align="center">Udice French Research Universities</td>
<td valign="bottom" align="center">82</td>
<td valign="bottom" align="center">2.24</td>
<td valign="bottom" align="center">10</td>
<td valign="bottom" align="center">Harvard University</td>
<td valign="bottom" align="center">0.06</td>
</tr>
<tr>
<td valign="bottom" align="center">11</td>
<td valign="bottom" align="center">University of California San Francisco</td>
<td valign="bottom" align="center">82</td>
<td valign="bottom" align="center">2.24</td>
<td valign="bottom" align="center">11</td>
<td valign="bottom" align="center">University Texas MD Anderson Cancer Ctr</td>
<td valign="bottom" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">12</td>
<td valign="bottom" align="center">Brigham Women S Hospital</td>
<td valign="bottom" align="center">81</td>
<td valign="bottom" align="center">2.213</td>
<td valign="bottom" align="center">12</td>
<td valign="bottom" align="center">University Calif Los Angeles</td>
<td valign="bottom" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">13</td>
<td valign="bottom" align="center">University of Queensland</td>
<td valign="bottom" align="center">78</td>
<td valign="bottom" align="center">2.131</td>
<td valign="bottom" align="center">13</td>
<td valign="bottom" align="center">Erasmus MC</td>
<td valign="bottom" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">14</td>
<td valign="bottom" align="center">State University System of Florida</td>
<td valign="bottom" align="center">70</td>
<td valign="bottom" align="center">1.913</td>
<td valign="bottom" align="center">14</td>
<td valign="bottom" align="center">Dana Farber Cancer Inst</td>
<td valign="bottom" align="center">0.05</td>
</tr>
<tr>
<td valign="bottom" align="center">15</td>
<td valign="bottom" align="center">Queen Mary University London</td>
<td valign="bottom" align="center">66</td>
<td valign="bottom" align="center">1.803</td>
<td valign="bottom" align="center">15</td>
<td valign="bottom" align="center">University Penn</td>
<td valign="bottom" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">16</td>
<td valign="bottom" align="center">H Lee Moffitt Cancer Center Research Institute</td>
<td valign="bottom" align="center">64</td>
<td valign="bottom" align="center">1.749</td>
<td valign="bottom" align="center">16</td>
<td valign="bottom" align="center">Kings Coll London</td>
<td valign="bottom" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">17</td>
<td valign="bottom" align="center">Memorial Sloan Kettering Cancer Center</td>
<td valign="bottom" align="center">61</td>
<td valign="bottom" align="center">1.667</td>
<td valign="bottom" align="center">17</td>
<td valign="bottom" align="center">Brigham &amp; Womens Hospital</td>
<td valign="bottom" align="center">0.04</td>
</tr>
<tr>
<td valign="bottom" align="center">18</td>
<td valign="bottom" align="center">University of Pennsylvania</td>
<td valign="bottom" align="center">58</td>
<td valign="bottom" align="center">1.585</td>
<td valign="bottom" align="center">18</td>
<td valign="bottom" align="center">University Queensland</td>
<td valign="bottom" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">19</td>
<td valign="bottom" align="center">Institution National De La Sante Et De La Recherche Medical Inserm</td>
<td valign="bottom" align="center">56</td>
<td valign="bottom" align="center">1.53</td>
<td valign="bottom" align="center">19</td>
<td valign="bottom" align="center">University Miami</td>
<td valign="bottom" align="center">0.03</td>
</tr>
<tr>
<td valign="bottom" align="center">20</td>
<td valign="bottom" align="center">University of Dundee</td>
<td valign="bottom" align="center">56</td>
<td valign="bottom" align="center">1.53</td>
<td valign="bottom" align="center">20</td>
<td valign="bottom" align="center">University Arizona</td>
<td valign="bottom" align="center">0.03</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>According to the statistics of intermediary centrality, Queen Mary University London has the highest intermediary centrality (0.11), indicating that it is a hub connecting other institutions (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>).</p>
<p>Based on VOSviewer software, a collaboration atlas of CSCC research institutions was established. A total of 4,287 institutions were included in the study, and 63 institutions with more than 20 publications were selected to form the collaboration atlas, which was divided into 7 clusters. Among the institutions shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>, the total link strength value of the University of Sydney is 151, indicating that this institution has the most co-occurrence times with other institutions. As shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>, Massachusetts General Hospital has been cited the most times (6390 times), indicating that its literature publication quality is high and widely recognized.</p>
<p>In the field of programmed death of CSCC cells, Harvard University still Published the most papers (20), accounting for 12.82% of the total publications. <italic>Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use</italic> is the most cited article on procedural death of skin cancer, with a total of 67 citations, published in <italic>Clinical Cancer Research</italic>, with an impact factor of 13.2. There are 19 institutions that have published more than 3 papers in this field. Except the University of Sydney, other institutions have close research exchanges. <xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4E, F</bold>
</xref>.</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Principal author analysis</title>
<p>Harwood CA (Queen Mary University London) has published 36 papers so far. Tommasino M (World Health Organization) ranks second with 35 publications. Proby CM (University of Dundee) ranked the third with 34 publications. The author with the highest H-index was Schmults CD (Harvard University), with a total of 31 publications, and the H-index was 18, that is, Schmults CD had at least 18 literatures being cited 18 times, as shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref> and <xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The author&#x2019;s published literature. <bold>(A)</bold>. The number of CSCC articles published by the top 10 authors and the H-index. <bold>(B)</bold>. CSCC&#x2019;s overlay visualization map of the top authors collaboration. <bold>(C)</bold>. CSCC&#x2019;s density visualization map of the top authors collaboration. <bold>(D)</bold>. Excellent author&#x2019;s co-citation analysis in the CSCC procedural death field.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g005.tif"/>
</fig>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>The number of articles published by the author and h-index.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Author</th>
<th valign="bottom" align="center">publication</th>
<th valign="bottom" align="center">h-index</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">Harwood CA</td>
<td valign="bottom" align="center">36</td>
<td valign="bottom" align="center">17</td>
</tr>
<tr>
<td valign="bottom" align="center">Tommasino M</td>
<td valign="bottom" align="center">35</td>
<td valign="bottom" align="center">14</td>
</tr>
<tr>
<td valign="bottom" align="center">Proby CM</td>
<td valign="bottom" align="center">34</td>
<td valign="bottom" align="center">15</td>
</tr>
<tr>
<td valign="bottom" align="center">Gupta R</td>
<td valign="bottom" align="center">33</td>
<td valign="bottom" align="center">10</td>
</tr>
<tr>
<td valign="bottom" align="center">Arron ST</td>
<td valign="bottom" align="center">32</td>
<td valign="bottom" align="center">14</td>
</tr>
<tr>
<td valign="bottom" align="center">Clark JR</td>
<td valign="bottom" align="center">32</td>
<td valign="bottom" align="center">16</td>
</tr>
<tr>
<td valign="bottom" align="center">Schmults CD</td>
<td valign="bottom" align="center">31</td>
<td valign="bottom" align="center">18</td>
</tr>
<tr>
<td valign="bottom" align="center">Pawlita M</td>
<td valign="bottom" align="center">30</td>
<td valign="bottom" align="center">13</td>
</tr>
<tr>
<td valign="bottom" align="center">Waterboer T</td>
<td valign="bottom" align="center">29</td>
<td valign="bottom" align="center">12</td>
</tr>
<tr>
<td valign="bottom" align="center">Wang XL</td>
<td valign="bottom" align="center">28</td>
<td valign="bottom" align="center">9</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Based on VOSviewer software, an author collaboration atlas of CSSS was established. A total of 18,426 authors had published relevant literatures, and 81 authors with more than 10 literatures were selected to form an institutional collaboration atlas, which was divided into 5 clusters. Among the authors shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>, the yellow cluster centered on Schmults CD (Harvard University), who was cited the most times. <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5C</bold>
</xref> indicated that Schmults CD (Harvard University) has the highest density, suggesting that his literature is of high quality and is still recognized by other authors in this field. As shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5D</bold>
</xref>, there were only 6 scientists who published more than 5 articles. Fury and Matthew G were closely associated with other authors.</p>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Analysis of journals and publishers</title>
<p>
<xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref> lists the top 25 journals and journals which had published the most relevant literatures in the field, as shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>. The top 3 journals were <italic>JOURNAL OF CUTANEOUS PATHOLOGY</italic> (128 articles), <italic>JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY</italic> (95 articles) and <italic>AMERICAN JOURNAL OF DERMATOLOGY DERMATOPATHOLOGY</italic> (74 articles). The top three publishers were <italic>Wiley</italic> (751 articles), <italic>Elsevier</italic> (667 articles) and <italic>Springer Nature</italic> (426 articles), which published more than 50 percent of all publications.</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Journal and publisher statistics.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Publication Titles</th>
<th valign="middle" align="center">Record Count</th>
<th valign="middle" align="center">% of 3,661</th>
<th valign="middle" align="center">Rank</th>
<th valign="middle" align="center">Publishers</th>
<th valign="middle" align="center">Record Count</th>
<th valign="middle" align="center">% of 3,661</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">JOURNAL OF CUTANEOUS PATHOLOGY</td>
<td valign="middle" align="center">128</td>
<td valign="middle" align="center">3.496</td>
<td valign="middle" align="center">1</td>
<td valign="middle" align="center">Wiley</td>
<td valign="middle" align="center">751</td>
<td valign="middle" align="center">20.514</td>
</tr>
<tr>
<td valign="middle" align="center">2</td>
<td valign="middle" align="center">JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY</td>
<td valign="middle" align="center">95</td>
<td valign="middle" align="center">2.595</td>
<td valign="middle" align="center">2</td>
<td valign="middle" align="center">Elsevier</td>
<td valign="middle" align="center">667</td>
<td valign="middle" align="center">18.219</td>
</tr>
<tr>
<td valign="middle" align="center">3</td>
<td valign="middle" align="center">AMERICAN JOURNAL OF DERMATOPATHOLOGY</td>
<td valign="middle" align="center">74</td>
<td valign="middle" align="center">2.021</td>
<td valign="middle" align="center">3</td>
<td valign="middle" align="center">Springer Nature</td>
<td valign="middle" align="center">426</td>
<td valign="middle" align="center">11.636</td>
</tr>
<tr>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">JOURNAL OF INVESTIGATIVE DERMATOLOGY</td>
<td valign="middle" align="center">67</td>
<td valign="middle" align="center">1.83</td>
<td valign="middle" align="center">4</td>
<td valign="middle" align="center">Lippincott Williams &amp; Wilkins</td>
<td valign="middle" align="center">228</td>
<td valign="middle" align="center">6.228</td>
</tr>
<tr>
<td valign="middle" align="center">5</td>
<td valign="middle" align="center">BRITISH JOURNAL OF DERMATOLOGY</td>
<td valign="middle" align="center">63</td>
<td valign="middle" align="center">1.721</td>
<td valign="middle" align="center">5</td>
<td valign="middle" align="center">Sage</td>
<td valign="middle" align="center">116</td>
<td valign="middle" align="center">3.169</td>
</tr>
<tr>
<td valign="middle" align="center">6</td>
<td valign="middle" align="center">PLOS ONE</td>
<td valign="middle" align="center">61</td>
<td valign="middle" align="center">1.666</td>
<td valign="middle" align="center">6</td>
<td valign="middle" align="center">Mdpi</td>
<td valign="middle" align="center">87</td>
<td valign="middle" align="center">2.376</td>
</tr>
<tr>
<td valign="middle" align="center">7</td>
<td valign="middle" align="center">HEAD AND NECK JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK</td>
<td valign="middle" align="center">60</td>
<td valign="middle" align="center">1.639</td>
<td valign="middle" align="center">7</td>
<td valign="middle" align="center">Taylor &amp; Francis</td>
<td valign="middle" align="center">79</td>
<td valign="middle" align="center">2.158</td>
</tr>
<tr>
<td valign="middle" align="center">8</td>
<td valign="middle" align="center">JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY</td>
<td valign="middle" align="center">59</td>
<td valign="middle" align="center">1.612</td>
<td valign="middle" align="center">8</td>
<td valign="middle" align="center">Public Library Science</td>
<td valign="middle" align="center">69</td>
<td valign="middle" align="center">1.885</td>
</tr>
<tr>
<td valign="middle" align="center">9</td>
<td valign="middle" align="center">JAMA DERMATOLOGY</td>
<td valign="middle" align="center">53</td>
<td valign="middle" align="center">1.448</td>
<td valign="middle" align="center">9</td>
<td valign="middle" align="center">Amer Medical Assoc</td>
<td valign="middle" align="center">68</td>
<td valign="middle" align="center">1.857</td>
</tr>
<tr>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">DERMATOLOGIC SURGERY</td>
<td valign="middle" align="center">44</td>
<td valign="middle" align="center">1.202</td>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">Amer Assoc Cancer Research</td>
<td valign="middle" align="center">66</td>
<td valign="middle" align="center">1.803</td>
</tr>
<tr>
<td valign="middle" align="center">11</td>
<td valign="middle" align="center">EXPERIMENTAL DERMATOLOGY</td>
<td valign="middle" align="center">38</td>
<td valign="middle" align="center">1.038</td>
<td valign="middle" align="center">11</td>
<td valign="middle" align="center">Frontiers Media Sa</td>
<td valign="middle" align="center">62</td>
<td valign="middle" align="center">1.694</td>
</tr>
<tr>
<td valign="middle" align="center">12</td>
<td valign="middle" align="center">INTERNATIONAL JOURNAL OF DERMATOLOGY</td>
<td valign="middle" align="center">34</td>
<td valign="middle" align="center">0.929</td>
<td valign="middle" align="center">12</td>
<td valign="middle" align="center">Karger</td>
<td valign="middle" align="center">61</td>
<td valign="middle" align="center">1.666</td>
</tr>
<tr>
<td valign="middle" align="center">13</td>
<td valign="middle" align="center">JOURNAL OF CUTANEOUS MEDICINE AND SURGERY</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">0.819</td>
<td valign="middle" align="center">13</td>
<td valign="middle" align="center">Spandidos Publ Ltd</td>
<td valign="middle" align="center">59</td>
<td valign="middle" align="center">1.612</td>
</tr>
<tr>
<td valign="middle" align="center">14</td>
<td valign="middle" align="center">SCIENTIFIC REPORTS</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">0.819</td>
<td valign="middle" align="center">14</td>
<td valign="middle" align="center">Oxford University Press</td>
<td valign="middle" align="center">56</td>
<td valign="middle" align="center">1.53</td>
</tr>
<tr>
<td valign="middle" align="center">15</td>
<td valign="middle" align="center">JOURNAL OF DERMATOLOGICAL SCIENCE</td>
<td valign="middle" align="center">29</td>
<td valign="middle" align="center">0.792</td>
<td valign="middle" align="center">15</td>
<td valign="middle" align="center">Bmj Publishing Group</td>
<td valign="middle" align="center">34</td>
<td valign="middle" align="center">0.929</td>
</tr>
<tr>
<td valign="middle" align="center">16</td>
<td valign="middle" align="center">JOURNAL OF DERMATOLOGY</td>
<td valign="middle" align="center">28</td>
<td valign="middle" align="center">0.765</td>
<td valign="middle" align="center">16</td>
<td valign="middle" align="center">Cureus Inc</td>
<td valign="middle" align="center">32</td>
<td valign="middle" align="center">0.874</td>
</tr>
<tr>
<td valign="middle" align="center">17</td>
<td valign="middle" align="center">CUREUS</td>
<td valign="middle" align="center">26</td>
<td valign="middle" align="center">0.71</td>
<td valign="middle" align="center">17</td>
<td valign="middle" align="center">Hindawi Publishing Group</td>
<td valign="middle" align="center">32</td>
<td valign="middle" align="center">0.874</td>
</tr>
<tr>
<td valign="middle" align="center">18</td>
<td valign="middle" align="center">ARCHIVES OF DERMATOLOGICAL RESEARCH</td>
<td valign="middle" align="center">24</td>
<td valign="middle" align="center">0.656</td>
<td valign="middle" align="center">18</td>
<td valign="middle" align="center">Wolters Kluwer Medknow Publications</td>
<td valign="middle" align="center">32</td>
<td valign="middle" align="center">0.874</td>
</tr>
<tr>
<td valign="middle" align="center">19</td>
<td valign="middle" align="center">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</td>
<td valign="middle" align="center">24</td>
<td valign="middle" align="center">0.656</td>
<td valign="middle" align="center">19</td>
<td valign="middle" align="center">Int Inst Anticancer Research</td>
<td valign="middle" align="center">28</td>
<td valign="middle" align="center">0.765</td>
</tr>
<tr>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">ACTA DERMATO VENEREOLOGICA</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">E-Century Publishing Corp</td>
<td valign="middle" align="center">26</td>
<td valign="middle" align="center">0.71</td>
</tr>
<tr>
<td valign="middle" align="center">21</td>
<td valign="middle" align="center">ANTICANCER RESEARCH</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
<td valign="middle" align="center">21</td>
<td valign="middle" align="center">Acta Dermato-Venereologica</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
</tr>
<tr>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center">FRONTIERS IN ONCOLOGY</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center">Dove Medical Press Ltd</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
</tr>
<tr>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">0.628</td>
<td valign="middle" align="center">23</td>
<td valign="middle" align="center">Thieme Medical Publishers</td>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center">0.601</td>
</tr>
<tr>
<td valign="middle" align="center">24</td>
<td valign="middle" align="center">CLINICAL AND EXPERIMENTAL DERMATOLOGY</td>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center">0.601</td>
<td valign="middle" align="center">24</td>
<td valign="middle" align="center">Edizioni Minerva Medica</td>
<td valign="middle" align="center">21</td>
<td valign="middle" align="center">0.574</td>
</tr>
<tr>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">JOURNAL OF DRUGS IN DERMATOLOGY</td>
<td valign="middle" align="center">21</td>
<td valign="middle" align="center">0.574</td>
<td valign="middle" align="center">25</td>
<td valign="middle" align="center">Journal Of Drugs In Dermatology</td>
<td valign="middle" align="center">21</td>
<td valign="middle" align="center">0.574</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Statistic on the number of journals and magazines published. <bold>(A)</bold>.Statistical chart of the number of publications in journals. <bold>(B)</bold>.Statistical chart of the number of publications in publishers.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g006.tif"/>
</fig>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Research hotspot analysis</title>
<p>Keywords co-occurrence analysis was performed using VOSviewer software. 159 keywords out of 12,704 keywords were included in the network based on the inclusion criteria of more than 30 times of common occurrence, as shown in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>. According to the keyword co-occurrence atlas, studies on squamous cell carcinoma of the skin were divided into 5 categories (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>): mechanism (red), treatment (purple), clinical (green), cancer (blue), and genetics (yellow). As shown in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>, the closer the circle is to green, the earlier the keyword appears. The closer the circle is to yellow, the later the keyword appears. <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref> is the density map of keywords. The closer the color of the keyword is to yellow, the higher the frequency of keyword occurrence. Squamous cell carcinoma, cancer, head and expression are highly popular keywords.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Keyword analysis diagram. <bold>(A)</bold>. Network visualization map of co-occurrence and clustering analysis of the frequent keywords. <bold>(B)</bold>.Co-occurrence and cluster analysis of frequent keywords in time-superimposed network visualization. <bold>(C)</bold>. Co-occurrence and cluster analysis of frequent keywords by density superposition network visualization. <bold>(D)</bold>.Keywords with the strongest citation bursts of CSCC. <bold>(E)</bold>. Keywords with the strongest citation bursts of programmed cell death in CSCC.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g007.tif"/>
</fig>
<p>The word frequency growth algorithm based on CiteSpace can calculate the rapid growth of professional words in a short time and analyze the development trend of the research field of CSCC (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7D</bold>
</xref>). Before 2017, the keywords that popped up were individual, mice, of the literature, vemurafenib, ras mutation, metastatic melanoma, dabrafenib, Raf inhibitor, tissue, BRAF inhibitor and braf are mostly related to mechanism therapy and prognosis. Between 2019 and 2022, improved survival, American joint committee, keratinocyte carcinoma, high risk, cutaneous metastasis, immune checkpoint inhibitor, mechanism, reconstruction, outcm, most of which were related to the tumor. Through clinical randomized and retrospective studies, the prognostic factors affecting the survival rate of patients can be identified, which can help clinicians choose more reasonable treatment plans and improve the survival rate of patients.</p>
<p>The word spectrum of programmed cell death keywords in CSCC was completely different from that in CSCC. The hot keywords from 2021to middle 2022 were cutaneous squamous cell carcinoma, diagnosis, pd 1, head, nivolumab and risk. The keywords in 2022 were mostly related to immunotherapy. Clinical studies of both CSCC and programmed cell death have focused on therapy (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7E</bold>
</xref>).</p>
<p>According to the timespan cluster map generated by CiteSpace software (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref>), keywords in the field of CSCC from 2012 to middle 2022 can be divided into 7 clusters: cutaneous squamous cell carcinoma, sentinel lymph node biopsy, skin cancer, BRAF inhibitor, human papillomaviruses and human papillomaviruses and P63 expression. The size, average contour value and representative keywords of each cluster were shown in <xref ref-type="table" rid="T6">
<bold>Table&#xa0;6</bold>
</xref>. The appendix shows the specific content of keyword clustering.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Keyword clustering atlas. <bold>(A)</bold>. Keyword clustering atlas of CSCC. <bold>(B)</bold>. Keyword clustering atlas in programmed cell death of CSCC.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1099382-g008.tif"/>
</fig>
<table-wrap id="T6" position="float">
<label>Table&#xa0;6</label>
<caption>
<p>Summary of the largest 7 clusters.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="center">Cluster ID</th>
<th valign="bottom" align="center">Size</th>
<th valign="bottom" align="center">Silhouette</th>
<th valign="bottom" align="center">Label (LLR)</th>
<th valign="bottom" align="center">Average Year</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="center">0</td>
<td valign="bottom" align="center">171</td>
<td valign="bottom" align="center">0.661</td>
<td valign="bottom" align="center">cutaneous squamous cell carcinoma (11481.56, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">1</td>
<td valign="bottom" align="center">102</td>
<td valign="bottom" align="center">0.751</td>
<td valign="bottom" align="center">sentinel lymph node biopsy (7017.67, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">2</td>
<td valign="bottom" align="center">96</td>
<td valign="bottom" align="center">0.699</td>
<td valign="bottom" align="center">skin cancer (19537.04, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">3</td>
<td valign="bottom" align="center">84</td>
<td valign="bottom" align="center">0.719</td>
<td valign="bottom" align="center">braf inhibitor (4589.85, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">4</td>
<td valign="bottom" align="center">72</td>
<td valign="bottom" align="center">0.693</td>
<td valign="bottom" align="center">human papillomaviruses (4615.5, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">5</td>
<td valign="bottom" align="center">46</td>
<td valign="bottom" align="center">0.759</td>
<td valign="bottom" align="center">actinic keratoses (3305.52, 1.0E-4)</td>
<td valign="bottom" align="center">2015</td>
</tr>
<tr>
<td valign="bottom" align="center">6</td>
<td valign="bottom" align="center">24</td>
<td valign="bottom" align="center">0.881</td>
<td valign="bottom" align="center">p63 expression (1259.36, 1.0E-4)</td>
<td valign="bottom" align="center">2014</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>CSCC is the second most common non-melanoma skin cancer, accounting for about 20% of skin cancers. However, a recent epidemiological study indicated that the ratio of basal cell carcinoma to squamous cell carcinoma in the medi-care population increased, even reaching 1:1 (<xref ref-type="bibr" rid="B17">17</xref>). According to data from the Mayo Clinic, the overall incidence of CSCC increased by 263% from 1976-1984 to 2000-2010 (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>Bibliometrics is a statistical method, which can conduct quantitative analysis on research papers of a certain topic by using specialized software through mathematical statistics (<xref ref-type="bibr" rid="B18">18</xref>), analyzing key research areas and predicting future research directions.</p>
<p>CiteSpace is a Web-based Java application that can perform data analysis and visualization of massive data (<xref ref-type="bibr" rid="B19">19</xref>), which often provides a direction for the analysis and future development of the research field through the aspects of co-citation, co-author and common keywords (<xref ref-type="bibr" rid="B20">20</xref>). VOSviewer is a software for literature analysis and knowledge visualization developed by Leiden University Research Center for Science and Technology (<xref ref-type="bibr" rid="B21">21</xref>), which can realize network construction and visualization. Compared with other visualization software, VOSviewer has advantages for novices in processing big data and drawing images, and can more clearly display hot spots and topics in the research field without adjustment (<xref ref-type="bibr" rid="B22">22</xref>). CiteSpace and VOSviewer are important visualization tools for information visualization and metrological atlas research in recent years.</p>
<p>From 2012 to middle 2022, a total of 3,656 CSCC-related papers were published, and annual average of publications was more than 250. The number of publications showed a wavy upward trend. In the field of CSCC, the United States ranks first in the number of published documents, the degree of close contact between countries and the value of central mediation. The research in this field is mainly focused on Dermatology, and more than 80% of the literatures related to skin squamous cell carcinoma are concentrated in the top 5 research fields. Most of the institutions in the CSCC field are affiliated with western countries. Harvard University is the most published institution. The University of Sydney works closely with other institutions. Queen Mary University London has the highest level of central intermediation. Wiley was the magazine publishing the most magazines, and JOURNAL OF CUTANEOUS PATHOLOGY was the Journal publishing the most related articles.</p>
<p>Cutaneous squamous cell carcinoma research falls into five broad categories: mechanism, treatment, clinical, cancer and genetics. Squamous cell carcinoma, cancer, head and expression are highly popular keywords. Keywords in the CSCC domain can be divided into 7 clusters: Cutaneous squamous cell carcinoma, Sentinel lymph node biopsy, skin cancer, BRAF inhibitor, human papillomaviruses and human Papillomaviruses and P63 expression. These key clusters and star keywords suggest that, through the joint exploration of clinical and basic research, it is helpful for clinicians to select a more reasonable treatment plan and improve the survival rate of patients to clarify the prognostic factors affecting CSCC patients.</p>
<p>Immunotherapy is considered a breakthrough in the treatment of advanced CSCC. The available clinical evidence is supported by strong preclinical theory. Programmed cell death has become a hot topic in the field of CSCC. In the 10 years from 2012 to 2022, a total of 156 research literatures were published, and the literatures gradually increased in 2016. The two fields of CSCC and CSCC seem to contain a relationship, but there is a big gap between them. The field of CSCC&#x2019;s programmed cell death is also centered on research institutions in western countries. Most studies are in the fields of immunotherapy and biotherapy, and the most prominent key word is PD-1. The most researches and treatments have been carried out on this protein. The study of programmed cell death in CSCC provides a bright development direction for CSCC therapy.</p>
<p>The content discussed in this topic is only a summary and induction of the literature published in the past, with limitations. Substantive research on CSCC programmed cell death will be carried out in clinical or scientific research in the future.</p>
</sec>
<sec id="s5" sec-type="conclusion">
<label>5</label>
<title>Conclusion</title>
<p>The study on the occurrence, development, treatment and prognosis of CSCC has become an important content in the tumor field. Programmed cell death studies in CSCC have led to key changes in advanced CSCC in terms of objective response, survival and quality of life improvement, and targeting the programmed cell death pathway could offer a concept of great promise for the treatment of CSCC.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>ZG contributed to the conceptualization of the study. YZ played a part in the acquisition and analysis of data, and validation and visualization of results. HW participated in drafting and reviewing the main manuscript. BL contributed to the project administration, and funding acquisition. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedberg</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Berry</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Moshiri</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yeh</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Attilasoy</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular mechanisms of cutaneous squamous cell carcinoma</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>(<issue>7</issue>):<elocation-id>3478</elocation-id>. doi: <pub-id pub-id-type="doi">10.3390/ijms23073478</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Schmults</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Cutaneous squamous cell carcinoma</article-title>. <source>Hematology/oncology Clinics North America</source> (<year>2019</year>) <volume>33</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.hoc.2018.08.001</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzic</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Schmitt</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Alniemi</surname> <given-names>DT</given-names>
</name>
<name>
<surname>Zubair</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Lourido</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: A population-based study in Olmsted county, Minnesota, 2000 to 2010</article-title>. <source>Mayo Clin Proc</source> (<year>2017</year>) <volume>92</volume>(<issue>6</issue>):<page-range>890&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.mayocp.2017.02.015</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueras Nart</surname> <given-names>I</given-names>
</name>
<name>
<surname>Cerio</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dirschka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Dr&#xe9;no</surname> <given-names>B</given-names>
</name>
<name>
<surname>Lear</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Pellacani</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Defining the actinic keratosis field: a literature review and discussion</article-title>. <source>J Eur Acad Dermatol Venereology JEADV</source> (<year>2018</year>) <volume>32</volume>:<page-range>544&#x2013;63</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jdv.14652</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Schmults</surname> <given-names>CD</given-names>
</name>
</person-group>. <article-title>Genomics of scc: tumor formation, progression, and future therapeutic implications for high-risk cutaneous squamous cell carcinoma</article-title>. In: <source>High-Risk Cutaneous Squamous Cell Carcinoma: A Practical Guide for Patient Management</source> <person-group person-group-type="editor">
<name>
<surname>Schmults</surname> <given-names>CD</given-names>
</name>
</person-group> (<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer Berlin Heidelberg</publisher-name>) (<year>2016</year>) <page-range>67&#x2013;102</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-662-47081-7:67-102</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Colegio</surname> <given-names>OR</given-names>
</name>
</person-group>. <article-title>Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment</article-title>. <source>Semin Oncol</source> (<year>2016</year>) <volume>43</volume>:<page-range>390&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1053/j.seminoncol.2016.02.019</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schierbeck</surname> <given-names>J</given-names>
</name>
<name>
<surname>Vestergaard</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bygum</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Skin cancer associated genodermatoses: A literature review</article-title>. <source>Acta dermato-venereologica</source> (<year>2019</year>) <volume>99</volume>:<page-range>360&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.2340/00015555-3123</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmood</surname> <given-names>N</given-names>
</name>
<name>
<surname>Rabbani</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>DNA Methylation readers and cancer: Mechanistic and therapeutic applications</article-title>. <source>Front Oncol</source> (<year>2019</year>) <volume>9</volume>:<elocation-id>489</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2019.00489</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martincorena</surname> <given-names>I</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Somatic mutation in cancer and normal cells</article-title>. <source>Sci (New York N.Y.).</source> (<year>2015</year>) <volume>349</volume>:<page-range>1483&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aab4082</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Text-graph enhanced knowledge graph representation learning</article-title>. <source>Front Artif Intell</source> (<year>2021</year>) <volume>4</volume>:<elocation-id>697856</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/frai.2021.697856</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Path-based knowledge reasoning with textual semantic information for medical knowledge graph completion</article-title>. <source>BMC Med Inf Decision Making</source> (<year>2021</year>) <volume>21</volume>:<fpage>335</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12911-021-01622-7</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zha</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>A bibliometric analysis using VOSviewer of publications on COVID-19</article-title>. <source>Ann Trans Med</source> (<year>2020</year>) <volume>8</volume>:<fpage>816</fpage>. doi: <pub-id pub-id-type="doi">10.21037/atm-20-4235</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>A VOSviewer-based bibliometric analysis of prescription refills</article-title>. <source>Front Med</source> (<year>2022</year>) <volume>9</volume>:<elocation-id>856420</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2022.856420</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Zhu H</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>XH</given-names>
</name>
</person-group>. <article-title>Study of acupuncture for low back pain in recent 20 years: a bibliometric analysis <italic>via</italic> CiteSpace</article-title>. <source>J Pain Res</source> (<year>2017</year>) <volume>10</volume>:<page-range>951&#x2013;64</page-range>. doi: <pub-id pub-id-type="doi">10.2147/JPR.S132808</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Liu J</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>LC</given-names>
</name>
</person-group>. <source>4th international conference on wireless communications</source>. <publisher-loc>Dalian, China</publisher-loc>: <publisher-name>Networking and Mobile Computing</publisher-name> (<year>2008</year>).</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dunford</surname> <given-names>MJS</given-names>
</name>
</person-group>. <article-title>Visualizing the intellectual structure and evolution of innovation systems research: a bibliometric analysis</article-title>. <source>Scientometrics</source> (<year>2015</year>) <volume>103</volume>:<page-range>135&#x2013;58</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11192-014-1517-y</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname> <given-names>H</given-names>
</name>
<name>
<surname>Weinstock</surname> <given-names>M</given-names>
</name>
<name>
<surname>Feldman</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the U.S. population, 2012</article-title>. <source>JAMA Dermatol</source> (<year>2015</year>) <volume>151</volume>(<issue>10</issue>):<page-range>1081&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2015.1187</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dubin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014)</article-title>. <source>Expert Opin Biol Ther</source> (<year>2014</year>) <volume>14</volume>:<page-range>1295&#x2013;317</page-range>. doi: <pub-id pub-id-type="doi">10.1517/14712598.2014.920813</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tseng</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace</article-title>. <source>Expert Opin Biol Ther</source> (<year>2012</year>) <volume>12</volume>:<fpage>593</fpage>&#x2013;<lpage>608</lpage>. doi: <pub-id pub-id-type="doi">10.1517/14712598.2012.674507</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>YP</given-names>
</name>
<name>
<surname>Gao X</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sui</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Knowledge domain and emerging trends in alzheimer's disease: a scientometric review based on CiteSpace analysis</article-title>. <source>Neural Regen Res</source> (<year>2019</year>) <volume>14</volume>:<page-range>1643&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.4103/1673-5374.255995</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Leydesdorff</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Patterns of connections and movements in dual-map overlays: A new method of publication portfolio analysis</article-title>. <source>J Ass Inf Sci Techn</source>, <publisher-name>Association for Information Science &amp; Technology</publisher-name> (<year>2014</year>) <volume>65</volume>(<issue>2</issue>):<page-range>334&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1002/asi.22968</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donthu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pattnaik</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Forty-five years of journal of business research: A bibliometric analysis - ScienceDirect</article-title>. <source>J Bus Res</source> (<year>2020</year>) <volume>109</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jbusres.2019.10.039</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>